Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies

  1. Rozner, R.N.
  2. Freites-Martinez, A.
  3. Shapiro, J.
  4. Geer, E.B.
  5. Goldfarb, S.
  6. Lacouture, M.E.
Aldizkaria:
Breast Cancer Research and Treatment

ISSN: 1573-7217,  0167-6806

Argitalpen urtea: 2019

Alea: 174

Zenbakia: 1

Orrialdeak: 15-26

Mota: Berrikuspena

DOI: 10.1007/S10549-018-4996-3 GOOGLE SCHOLAR
Datuen iturria: Scopus